Effect of Dalfampridine (4-AP) on Genioglossus Muscle Activity in Healthy Adults

• Status: Completed
• Trial end date: 2016-07-01
• Target enrollment: 0
• Participant gender: All

Summary

In this protocol the investigators will test the effect of dalfampridine (a potassium channel blocker) on genioglossus muscle activity (EMG GG) during wakefulness and sleep in healthy control subjects.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Brigham and Women's Hospital
• Treatments: 4-Aminopyridine

Criteria

Inclusion Criteria:

• Healthy control subjects

Exclusion Criteria:

• Cardiovascular disease other than well controlled hypertension

• History of seizures